Why are global pharmaceutical companies threatening to pull out of the Australian market?

Global drug manufacturers argue that Australia’s rigid pricing and approvals system provides very little commercial incentive to launch new products.

How does Donald Trump’s "Most Favoured Nation" policy impact drug availability in Australia?

The US "Most Favoured Nation" policy pressures American drugmakers to match the lower drug prices paid in overseas markets like Australia. Because selling medicines cheaply in Australia forces automatic price cuts in the highly lucrative US market, major pharmaceutical companies are choosing to delay or completely skip releasing new innovations in Australia to protect their US margins.

What specific medical sectors are most at risk from this pharmaceutical standoff in Australia?

According to Bristol Myers Squibb (NYSE: BMY), the pricing dispute will heavily restrict the local availability of breakthrough treatments across oncology, immunology, cardiovascular care, and neuroscience.

What is the current regulatory wait time for new drug approvals in Australia compared to overseas?

Data from a recent Medicines Australia report reveals that Australian patients face an average wait time of 3.6 years to access new medical treatments that are already fully approved and available in the US and Europe.

How much less does Australia pay for new medicines compared to international peers?

Australia pays roughly 31 per cent less for new medications than comparable wealthy economies like Canada. While this single-buyer leverage keeps taxpayer-funded health costs low, global suppliers argue the severe discounts have created an unsustainable market that no longer justifies the cost of local clinical trials and commercial distribution.

Image for illustrative purposes only. Not a real photo.

Pharma giants warn Australia risks missing new drugs

Written by Mahathir BayenaPublished Jun 1, 2026, 10:15 PM

Global pharmaceutical giants are warning that Australia risks being abandoned as a market for life-saving therapies due to a "prohibitive" pricing and approvals system.

Owen Smith, CEO of Bristol Myers Squibb’s Australian operations, warned that millions of patients could lose access to cutting-edge cancer, cardiovascular, and neuroscience treatments.

He urged the Albanese government to reform the Pharmaceutical Benefits Scheme, claiming the current setup offers little commercial incentive for drugmakers and has already sparked a "quiet progressive bleed of jobs", with major companies cutting up to 20% of their local workforces.

The crisis is intensified by US President Donald Trump’s "Most Favoured Nation" policy, which pressures US drugmakers to match the lower prices paid in overseas markets like Australia.

Selling medicines cheaply in Australia forces price cuts in the lucrative US market, leading multinationals to bypass Australia entirely.

While big pharma relies on the taxpayer-funded PBS to reach millions of Australians, Smith criticised an approvals process where new innovations are referenced against decades-old medicines.

According to a recent Medicines Australia report, local patients wait an average of 3.6 years for treatments already available in the US and Europe, and Australia pays 31% less for new medicines than comparable nations like Canada.

Although Health Minister Mark Butler is reviewing the pricing system, the Labor government refuses to bow to international pressure to alter its subsidised health model.

However, Smith warned that without urgent change, Australia will find itself trapped in the "slow lane" of global medicine.